Sinomenine Ameliorated Microglial Activation and Neuropathic Pain After Chronic Constriction Injury Via TGF-β1/ALK5/Smad3 Signalling Pathway

Sinomenine (SIN), a bioactive isoquinoline alkaloid extracted from the roots and stems of Sinomenium acutum, is efficacious against various chronic pain conditions. Inhibition of microglial activation at the spinal level contributes to the analgesic effects of SIN. Microglial activation in the spinal dorsal horn is key to sensitising neuropathic pain. Consequently, this study aimed to investigate whether the antinociceptive effects of SIN in neuropathic pain are induced through microglial inhibition and the underlying mechanisms. In this study, we observed that SIN alleviated chronic constriction injury (CCI)-induced pain hypersensitivity, spinal microglial activation and neuroinflammation. Consistently, SIN evoked the upregulation of transforming growth factor-beta1 (TGF-β1) and phosphorylated SMAD3 in the L4-6 ipsilateral spinal dorsal horn of CCI mice. Intrathecal injection of TGF-β1 siRNA and an activin receptor-like receptor (ALK5) inhibitor reversed SIN's antinociceptive and antimicroglial effects on CCI mice. Moreover, targeting SMAD3 in vitro with siRNA dampened the inhibitory effect of TGF-β1 on lipopolysaccharide-induced microglial activation. Finally, targeting SMAD3 abrogated SIN-induced pain relief and microglial inhibition in CCI mice. These findings indicate that the TGF-β1/ALK5/SMAD3 axis plays a key role in the antinociceptive effects of SIN on neuropathic pain, indicating its suppressive ability on microglia.

Smad3; activin receptor–like receptor 5; microglia; neuropathic pain; sinomenine; transforming growth factor‐β1.